Medical misdiagnoses are less about what a doctor knows and more about cognitive biases during the reasoning process. Errors occur when uncertainty is handled poorly, alternatives are ignored, or reflection is cut short. Strengthening clinical judgment through deliberate training is key to reducing these errors.

Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

The most valuable lessons in clinical trial design come from understanding what went wrong. By analyzing the protocols of failed studies, researchers can identify hidden biases, flawed methodologies, and uncontrolled variables, learning precisely what to avoid in their own work.

Landmark discoveries, like EGFR mutations, didn't start in a lab but with astute oncologists noticing patterns in how some patients responded to treatment while others didn't. This highlights that every patient interaction is a research opportunity, offering clues that can lead to the next scientific breakthrough.

Reflecting on his PhD, Terry Rosen emphasizes that experiments that fail are often the most telling. Instead of discarding negative results, scientists should analyze them deeply. Understanding *why* something didn't work provides critical insights that are essential for iteration and eventual success.

True scientific advancement happens when researchers refuse to accept 'no' as an answer. When immunotherapy was dismissed for lung cancer, pioneers investigated why it worked in melanoma but not other cancers. This mindset—questioning failures and studying successes—is key to turning scientific impossibilities into standard treatments.

Negative clinical trial results should not be seen as complete failures. Dr. Adam Arthur explains that even when an intervention fails its primary goal, the data provides crucial learnings that redirect research toward more promising pathways for patient care.

Biomarkers provide value beyond predicting patient response. Their core function is to answer 'why' a treatment succeeded or failed. This explanatory power informs sequential therapy decisions and provides crucial scientific insights that advance the entire medical field, not just the individual patient's case.

An oncology leader compares cancer research to elite sports. Success isn't about avoiding failure but about learning from a high volume of losses. Like athletes Michael Jordan and Roger Federer, researchers achieve greatness through persistence and resilience after countless setbacks.